Production (Stage)
Zevra Therapeutics, Inc.
ZVRA
$8.65
$0.080.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 91.33% | -7.57% | -66.75% | -19.87% | 16.44% |
| Total Depreciation and Amortization | 0.06% | 1.92% | 3.52% | 0.00% | 98.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.68% | 65.29% | 1,874.93% | 172.52% | -117.44% |
| Change in Net Operating Assets | -42.20% | -1,913.81% | 83.40% | -872.97% | 94.18% |
| Cash from Operations | 49.40% | 10.42% | 5.07% | -18.21% | -0.04% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 294.50% | 82.55% | -24,205.43% | -100.87% | -63.97% |
| Cash from Investing | 292.69% | 82.55% | -24,205.43% | -100.87% | 39.75% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | 148.62% | -98.77% | 13,392.71% | -60.56% | -80.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 101.88% | -98.77% | 322.47% | 1,159.65% | -75.68% |
| Foreign Exchange rate Adjustments | -155.44% | 236.66% | -253.92% | 808.89% | -112.89% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 117.55% | -237.05% | 511.79% | -1,694.50% | 9.09% |